Press release
Deadline on May 13th coming up in Lawsuit for Investors in Akebia Therapeutics, Inc. (NASDAQ: AKBA)
A Deadline is coming up on May 13, 2022, in the lawsuit for certain investors in Akebia Therapeutics, Inc. (NASDAQ: AKBA).
Investors who purchased shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) have certain options and there are strict and short deadlines running. Deadline: May 13, 2022. NASDAQ: AKBA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Eastern District of New York the plaintiff alleges on behalf of purchasers of Akebia Therapeutics, Inc. (NASDAQ: AKBA) common shares between June 28, 2018, and September 2, 2020, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between June 28, 2018 and September 2, 2020, the Defendants made false and/or misleading statements and/or failed to disclose that vadadustat was not as safe in treating NDD-CKD patients with anemia as Defendants had represented, that as a result, Defendants overstated the PRO2TECT Program's clinical prospects, that accordingly, Defendants also overstated vadadustat's overall commercial and regulatory prospects, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on May 13th coming up in Lawsuit for Investors in Akebia Therapeutics, Inc. (NASDAQ: AKBA) here
News-ID: 2618215 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Akebia
Chronic Kidney Disease Drugs Market Sees Growth With Dialysis Alternatives and D …
Chronic Kidney Disease Drugs Market Overview
Chronic Kidney Disease Drugs Market is estimated to be valued at USD 15.92 Billion in 2025 and is expected to reach USD 23.02 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032.
The latest report (2025-2032) on the Chronic Kidney Disease Drugs Market by Coherent Market Insights offers an in-depth analysis of market trends, growth factors, challenges, and competition.…
Investigation announced for Investors in shares of Akebia Therapeutics, Inc. (NA …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Akebia Therapeutics, Inc.
Investors who are current long term investors in Akebia Therapeutics, Inc. (NASDAQ: AKBA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: AKBA stocks follows a lawsuit filed against Akebia…
Lawsuit filed for Investors in shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA …
An investor, who purchased shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA), filed a lawsuit over alleged violations of Federal Securities Laws by Akebia Therapeutics, Inc.
Investors who purchased shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) have certain options and for certain investors are short and strict deadlines running. Deadline: May 13, 2022. NASDAQ: AKBA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Shares of Akebia…
Anemia And Other Blood Disorder Drugs Market 2020 Strategic Assessment - mgen In …
Anemia And Other Blood Disorder Drugs Global Market Report 2020 provides insightful data about business strategies, qualitative and quantitative analysis of Global Market. The report also calls for market - driven results deriving feasibility studies for client needs. MarketInsightsReports ensures qualified and verifiable aspects of market data operating in the real- time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in…
Hypoxia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results | Akebi …
Hypoxia is a condition characterized by inability of the tissues to receive an adequate oxygen supply. This condition is categorized into four types; hypoxic, stagnant, anaemic, fulminating, and histotoxic hypoxia. Hypoxic hypoxia is defined as the lack of oxygen in the arterial blood while in stagnant hypoxia, the rate at which blood circulates in the body is decreased.
Download the sample report @ https://www.pharmaproff.com/request-sample/1140
Fulminating hypoxia is an induced type of hypoxia…
Iron Deficiency Anemia Therapeutics- Pipeline Analysis 2018, Clinical Trials & R …
Iron deficiency anemia is a common type of anemia, which is a result of decreased level of haemoglobin in red blood cells (RBCs). There are several causes for iron deficiency anemia, such as inadequate iron intake, pregnancy or blood loss due to menstruation, internal bleeding, and body’s inability to absorb iron.
Download the sample report at: https://www.pharmaproff.com/request-sample/1042
The symptoms observed in patients with iron deficiency anemia are fatigue, weakness, pale skin,…
